JamesXunhaiXuMD

Oncology • North Bethesda, MD

Breast Cancer, Gastrointestinal Cancer, Genitourinary Oncology, Thoracic Cancer

Physician

Join to view full profile

Dr. Xu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Xu's full profile

Already have an account?

Office
6000 Executive Blvd
Ste 501
North Bethesda, MD 20852
Phone+1 240-618-0275

Fax+1 240-470-1518

Summary

Potomac Oncology and Hematology

As a fervent advocate for personalized medicine, Dr. Xu will take time to understand each patient's unique diagnosis and needs to formulate a treatment plan tai

Clinical Expertise

Personalized medicine, Breast cancer, Gastrointestinal oncology, Urologic oncology, Thoracic oncology

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2009 - 2012
Yale-New Haven Medical CenterResidency, Internal Medicine, 2007 - 2009
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Internship, Internal Medicine, 2006 - 2007
University of Minnesota Medical SchoolClass of 2006

Certifications & Licensure

MD State Medical License 2013 - 2025
DC State Medical License 2013 - 2024
NY State Medical License 2009 - 2014
RI State Medical License 2012 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Merit Award Conquer Cancer Foundation of American Society of Clinical Oncology, 2012
Young Investigator Award Conquer Cancer Foundation of American Society of Clinical Oncology, 2011

Publications & Presentations

PubMed

194 citations
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V. Ellen Maher, Laura L. Fernandes, Chana Weinstock, Shenghui Tang, Sundeep Agarwal
Journal of Clinical Oncology. 2019-05-22
6 citations
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration po...
Jaleh Fallah, Lijun Zhang, Anup K. Amatya, Yutao Gong, Bellinda L. King-Kallimanis
The Lancet. Oncology. 2021-09-01
10 citations
Targeting EGFR in Esophagogastric Cancer.
Steven Brad Maron, James Xu, Yelena Y. Janjigian
Frontiers in Oncology. 2020-12-08

Journal Articles

Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Xu,Xunhai, Strimpakos AS, Saif MW, Journal of Pancreas, 7/8/2012
Molecular testing in lung cancer: the time is now
cheng H, Xu X, Costa DB, Powell CA, Halmos B, Curr Oncol Rep, 9/12/2010

Abstracts/Posters

Immunocytochemistry staining for estrogen and progesterone receptor in circulating tumor cells: Concordance between primary and metastatic tumors
Bischoff FZ, Pham T, Wong KL, Villarin E, Xu Xu, Kalinsky K, Mayer JA, CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, 12/4/2012
Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing.
Xu X, Shen Y, Dewill W, Bischoff F, Hershman D, Kalinsky K, Journal of Clinical Oncology Supplement, Chicago, IL, American Society of Clinical Oncology Annual Meeting, 2012. http://meetinglibrary.asco, 6/2012
Bone Marrow Induced Myocardial Restoration in the Canine Model
Gallegos, RP, Jayaswal A, Clarkson C, Xu X, Bolman RM, O'Brien T, Verfaillie C, et al, American Society of Hematology, 2003